{"id":"W1538245709","doi":"10.1002/cncr.27758","title":"Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma","year":2012,"lang":"en","type":"article","venue":"Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Genentech; Abbott Laboratories","keywords":"Medicine; Internal medicine; Gastroenterology; Clinical endpoint; Adverse effect; Progression-free survival; Hepatocellular carcinoma; Liver function; Phases of clinical research; Progressive disease; Oncology; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001698524,0.001604956,0.001274085,0.0003525972,0.0002934145,0.0005902211,0.0004897072,0.0007904676,0.004274377],"category_scores_gemma":[0.0007781958,0.0004325781,0.0006408814,0.0002884805,0.0005393835,0.0005802612,0.0003317081,0.002025101,0.0009956544],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006324026,"about_ca_system_score_gemma":0.001285091,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005218111,"about_ca_topic_score_gemma":0.001311415,"domain_scores_codex":[0.9996943,0.0001819935,0.00001457523,0.00003472496,0.00002681899,0.00004766398],"domain_scores_gemma":[0.9995266,0.00008100412,0.000117895,0.00002512947,0.00003021233,0.0002191151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7549372,0.05570461,0.01037546,0.001607943,0.001346908,0.0006390234,0.0003176405,0.003559642,0.05041649,0.0003147567,0.006823389,0.113957],"study_design_scores_gemma":[0.7683923,0.2155382,0.008126388,0.00004107803,0.0002574765,0.0004538907,0.00003591473,0.001367827,0.003136507,0.0001202195,0.002510891,0.0000192362],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914007,0.002365596,0.000554651,0.000803581,0.0001376749,0.002522105,0.0007243383,0.0001017152,0.001389577],"genre_scores_gemma":[0.9867843,0.00194632,0.001767886,0.0009814266,0.0002918098,0.003450407,0.001913272,0.0000276026,0.002836973],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004274377,"threshold_uncertainty_score":0.01429921,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09270249027125183,"score_gpt":0.3175934619452295,"score_spread":0.2248909716739776,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}